
Vivek Subbiah/LinkedIn
Apr 10, 2025, 10:57
Vivek Subbiah: Editorial on Emerging KRAS-Targeted Therapies Published in ASCO’s JCO OP
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn shared a recent post by Andrew J. Pellatt et al. published in JCO Oncology Practice.
“With so many KRAS targeted drugs entering clinical trials pleased to share our editorial in American Society of Clinical Oncology (ASCO) journal JCO OP
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.”
Authors: Andrew J. Pellatt et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 13, 2025, 05:56
Apr 13, 2025, 05:55
Apr 13, 2025, 05:10
Apr 13, 2025, 05:05
Apr 13, 2025, 04:50
Apr 13, 2025, 04:21